Skip to Primary Navigation

Skip to main content

CMS quietly rolls out new round of Medicare-negotiated drug prices

A wall of shelves holding many medicine bottles.
Photo: Spencer Platt/Getty Images

Kevin Kinsella

3 min read
 Click to share on Facebook (Opens in new window/tab) Click to share on Twitter (Opens in new window/tab) Click to share on LinkedIn (Opens in new window/tab) Click to share on WhatsApp (Opens in new window/tab)

The second-cycle negotiated-price drugs include medicines to treat cancer, asthma, and metabolic conditions.

The Centers for Medicare and Medicaid Services (CMS) quietly announced it negotiated down 2027 prices for 15 drugs following negotiations between the agency and individual drugmakers.

The announcement concludes three rounds of direct negotiations between CMS and the drugmakers and represents the second annual cycle of negotiations conducted through the Medicare Drug

, , , , , ,

Get full access, free for a month

Start your 28-day free trial to continue reading and access
all content on GRIP – no payment details required.

Start free trial Sign in

What’s included:

  • Every new article, plus our 5,000+ archive
  • Daily regulatory insight and guidance
  • Exclusive interviews and in-depth analysis
  • Coverage of industry-leading events and conferences
  • All podcasts and videos, featuring industry experts
  • The full set of Rules Navigator tools
  • An ad-free experience